Principia Biopharma Inc. Common Stock
PRNB
PRNB was delisted on the 25th of September, 2020.
74 hedge funds and large institutions have $671M invested in Principia Biopharma Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 30 increasing their positions, 11 reducing their positions, and 11 closing their positions.
173% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 11
127% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 11
19% more funds holding
Funds holding: 62 → 74 (+12)
1% more capital invested
Capital invested by funds: $667M → $671M (+$4.37M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$18.6M |
| 2 |
BlackRock
New York
|
+$16.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.89M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$7.62M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$31.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$9.86M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.24M |
| 4 |
RI
RTW Investments
New York
|
-$5.78M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$2.55M |
PRNB Hedge Fund Activity: Q2 2019 in Review
74 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Principia Biopharma Inc. Common Stock (PRNB) for Q2 2019, worth a combined $671M — up 0.65% from $667M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PRNB positions and 11 closed out — a net gain of 14 holders — while 30 added to existing stakes and 11 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $18.6M. The largest seller was OrbiMed, cutting an estimated $31.2M.
- 74 institutional investors held Principia Biopharma Inc. Common Stock (PRNB) as of Q2 2019, up from 62 in Q1 2019.
- Funds reported $671M of Principia Biopharma Inc. Common Stock stock for Q2 2019, up 0.65% quarter-over-quarter.
- 25 funds opened new Principia Biopharma Inc. Common Stock positions in Q2 2019 and 11 closed out, a net change of +14 holders.
- The largest Principia Biopharma Inc. Common Stock buyer in Q2 2019 was PFM Health Sciences, an estimated $18.6M added.
- The largest Principia Biopharma Inc. Common Stock seller in Q2 2019 was OrbiMed, an estimated $31.2M sold.
Based on aggregated 13F filings for Q2 2019.